Tomomitsu Sasaki

Medical R&D Division, 636-1 Iida Shinden, Nishi Ward
Saitama, 3310068, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.

Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.

Journal: Drug metabolism and pharmacokinetics

Published: October 29, 2019

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.

Journal: Clinical and experimental nephrology

Published: October 02, 2019

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.

Journal: Clinical and experimental nephrology

Published: October 01, 2019

The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.

The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.

Journal: Clinical and experimental nephrology

Published: September 30, 2019

Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.

Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.

Journal: Clinical and experimental nephrology

Published: September 30, 2019

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.

Journal: Clinical and experimental nephrology

Published: September 24, 2019

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.

Journal: Clinical and experimental nephrology

Published: September 16, 2019

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.

Journal: Clinical and experimental nephrology

Published: August 28, 2019

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Journal: Clinical and experimental nephrology

Published: September 12, 2017

Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.

Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.

Journal: Clinical rheumatology

Published: October 12, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026